Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
Status:
Completed
Trial end date:
2015-09-15
Target enrollment:
Participant gender:
Summary
This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study
assessing immunization responses to vaccination in adults with moderate to severe atopic
dermatitis who are treated with subcutaneous dupilumab.